10-Q: Entera Bio Reports First Quarter 2024 Results, Cites Progress in Oral Peptide Development

Entera Bio's first quarter 2024 results show a net loss of $2.017 million, with ongoing development of oral peptide therapies for osteoporosis and hypoparathyroidism.

Summary

• Entera Bio reported a net loss of $2.017 million for the first quarter of 2024, compared to a net loss of $2.190 million for the same period in 2023.
• Research and development expenses decreased to $0.7 million from $0.9 million year-over-year, primarily due to reduced clinical trial expenses.
• General and administrative expenses remained relatively stable at $1.3 million.
• The company's cash and cash equivalents stood at $9.2 million as of March 31, 2024.
• Entera Bio believes its current funds will support operations into the third quarter of 2025, but additional funding is needed for the Phase 3 study of EB613.
• The company is developing oral tablet formulations of peptide therapies, including EB613 for osteoporosis and EB612 for hypoparathyroidism.
• Entera Bio is also collaborating with OPKO Biologics on oral GLP-2 and OXM programs.
• The company has received grants from the Israeli Innovation Authority, which are subject to royalty payments on future revenues.

Sentiment

Score: 4

Explanation: The document highlights some positive developments in research and collaborations, but the company's financial situation and the going concern warning from auditors create a negative sentiment. The need for additional funding and the ongoing losses are significant concerns.

Positives

• The net loss decreased slightly compared to the same quarter last year.
• Research and development expenses decreased, indicating potential cost efficiencies.
• The company has made progress in its collaboration with OPKO Biologics, with positive in vivo results for the oral GLP-2 program.
• The company has received FDA concurrence that a 2-year, placebo-controlled phase 3 study with Total Hip BMD as primary endpoint could support a new drug application for EB613.
• The company has sufficient funds to operate into the third quarter of 2025.

Negatives

• The company continues to operate at a loss, with a net loss of $2.017 million for the quarter.
• The company's auditors have expressed substantial doubt about its ability to continue as a going concern.
• The company needs additional funding to commence the Phase 3 study of EB613.
• The company has an accumulated deficit of $106.4 million.
• The company has not generated any revenue from product sales.

Risks

• The company's ability to continue as a going concern is uncertain due to recurring losses and negative cash flows.
• The company needs to raise additional capital to fund its operations, particularly the Phase 3 study of EB613.
• The company's product development is subject to regulatory risks and uncertainties.
• The company's operations are located in Israel, which is subject to political and security risks.
• The company relies on third parties for clinical trials and manufacturing, which could lead to delays or supply issues.
• The company may not be able to obtain or maintain patent protection for its product candidates.

Future Outlook

Entera Bio expects to continue to incur significant expenses and losses for the foreseeable future as it advances its product candidates through development. The company believes its existing cash resources will be sufficient to meet its projected operating requirements into the third quarter of 2025, but additional funding will be required for the Phase 3 study of EB613.

Management Comments

• Management is of the opinion that its available funds as of March 31, 2024 will allow the Company to operate under its current plans into the third quarter of 2025.
• Management continually evaluates various financing alternatives in the public and private equity markets, debt financing and strategic collaborations.
• Management is of the opinion that there is substantial doubt as to the Company's ability to continue as a going concern.

Industry Context

The company is operating in the competitive biopharmaceutical industry, focusing on oral delivery of peptide therapies, which is a challenging area. The company's focus on osteoporosis and hypoparathyroidism addresses significant unmet medical needs. The collaboration with OPKO Biologics on GLP-2 and OXM programs aligns with the growing interest in these peptides for metabolic disorders.

Comparison to Industry Standards

• Entera Bio's focus on oral peptide delivery is a differentiator compared to companies relying on injectable therapies, such as Amgen (Prolia) and Eli Lilly (Forteo) in the osteoporosis space.
• The company's collaboration with OPKO Biologics on GLP-2 and OXM programs puts it in competition with companies like Zealand Pharma and Novo Nordisk, which are also developing GLP-2 and GLP-1/glucagon agonists.
• The company's cash burn rate is typical for a clinical-stage biotech company, but the need for additional funding is a common challenge in the industry.
• The company's accumulated deficit is significant, which is not uncommon for companies in the early stages of drug development.

Stakeholder Impact

• Shareholders face the risk of dilution if the company raises additional capital through equity offerings.
• Employees may be affected by the company's financial instability and potential need for cost-cutting measures.
• Patients may benefit from the development of new oral peptide therapies for osteoporosis and hypoparathyroidism.
• The company's suppliers and creditors may be impacted by the company's financial situation.

Next Steps

• The company plans to initiate a Phase 3 registrational study for EB613 for osteoporosis.
• The company expects additional in vivo PK/PD data from both the oral GLP-2 tablet program and the oral OXM tablet program in 2024.
• An investigator sponsored phase 2 study is expected to be initiated with respect to the treatment of stress fractures in athletes in the second half of 2024.

Key Dates

Keywords

oral peptide, osteoporosis, hypoparathyroidism, EB613, EB612, GLP-2, OXM, clinical trials, N-Tab technology, biopharmaceutical